We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Evolutionary Perspectives
-
1. Antibiotic resistance: a mechanistic overview
- Dr. Neil Woodford
-
2. Mutation
- Prof. Stephen Gillespie
-
3. Fitness in antibiotic resistant bacteria
- Prof. Stephen Gillespie
- Epidemiology and Clinical Impact
-
4. Risk factors for antibiotic resistance in Streptococcus pneumoniae
- Prof. Keith Klugman
-
5. Beta-lactamases: clinical impact and epidemiology
- Prof. Sebastian Amyes
-
6. Antiretroviral drug resistance
- Prof. Deenan Pillay
-
7. Malaria - changing paradigms
- Dr. Janet Cox-Singh
-
8. Advances in mode of action of antimalarials and resistance mechanisms 1
- Prof. David Warhurst
-
9. Advances in mode of action of antimalarials and resistance mechanisms 2
- Prof. David Warhurst
-
10. HCV resistance
- Prof. John Dillon
- Diagnosis and Surveillance of Resistance
-
11. Conventional and automated diagnostic methods
- Dr. Alan Johnson
-
12. National and international surveillance of antibiotic resistance 1
- Prof. David Livermore
-
13. National and international surveillance of antibiotic resistance 2
- Prof. David Livermore
-
14. Innovative approaches to rapid antibiotic resistance testing
- Dr. Robert Hammond
- The Antibiotic Resistance Future
-
15. Medicinal chemistry strategies in combating antibiotic resistance
- Dr. Geoffrey Coxon
-
16. Teixobactin kills pathogens without detectable resistance
- Prof. Kim Lewis
- Archived Lectures *These may not cover the latest advances in the field
-
17. Molecular diagnosis of antibiotic resistance
- Dr. Tim McHugh
-
18. Introduction to malaria
- Prof. David Warhurst
-
19. Fitness and compensation
- Dr. Sébastian Gagneux
-
20. Antibiotic resistance and the supragenome hypothesis
- Dr. Bambos Charalambous
-
21. Methicillin resistant S. aureus and other resistances
- Prof. Mark Enright
-
22. Glycopeptide-resistant enterococci
- Dr. Neil Woodford
-
23. Drug resistant tuberculosis: biology, epidemiology and control
- Dr. Christopher Dye
-
24. Controlling antibiotic resistance in the hospital environment
- Dr. Ian Eltringham
-
25. Controlling antibiotic resistance in the community
- Dr. Peter Wilson
-
26. Public policy to reduce antibiotic resistance
- Dr. Niels Frimodt-Møller
-
27. Overcoming resistance through novel drug targets
- Prof. Anthony Coates
Printable Handouts
Navigable Slide Index
- Introduction
- HCV virology
- HCV genotype
- HCV phylogenetics
- HCV genome codes for specific proteins
- HCV genome representation
- HCV replication and Resistance-Associated Substitutions (RAS)
- Defining a polymorphism
- Thresholds of clinical relevance HCV resistance to DAAs*
- Options to deal with RAS
- Scenarios where resistance testing is recommended
- Considerations with current antiviral regimens elbasvir/grazoprevir
- Ledipasvir/sofosbuvir
- Glecaprevir/pibrentasvir
- Sofosbuvir/velpatasvir
- Sofosbuvir/velpatasvir/voxilaprevir
- Common, clinically important RASs?
- Clinically important RASs by DAA regimen
- Clinically-relevant RAS: options
Topics Covered
- Hepatitis C virus (HCV)
- HCV virology
- HCV genotype
- HCV phylogenetics
- Resistance-Associated Substitutions (RAS)
- Polymorphisms
- Current antiviral regimens
- Clinically-relevant RAS
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Dillon, J. (2025, May 29). HCV resistance [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved July 1, 2025, from https://doi.org/10.69645/JSXK5152.Export Citation (RIS)
Publication History
- Published on May 29, 2025
Financial Disclosures
- Prof. Dillon has received lecture fees and institutional research grants from Gilead, MSD and Abbvie.
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is
Professor John Dillon
of University of Dundee.
I'm a professor of hepatology,
and I'm going to talk today
about HCV resistance.
0:11
HCV is a virus.
It's an enveloped virus.
It's a single-stranded,
positive-sense RNA virus.
It's a part of the
Flaviviridae genus,
or family rather,
and is its own genus.
The genome length of
approximately 9.6 kilobases.
0:32
There are seven HCV genotypes,
although a probable eighth
genotype has been described,
and within each of
those genotypes
there are multiple subtypes.
There are six main
genotypes worldwide.
Genotype 7 and genotype
8 don't have much
therapeutic implications.
Each genotype has a reference
nucleotide sequence
and, therefore, an
amino acid sequence,
and a substitution.
A difference in amino acid at
a defined position
of the HCV protein
between a patient's HCV and
the reference HCV protein
is termed a substitution.
You'd also think of
it as a polymorphism,
in more generic terms,
and that's the terminology that's
still preferred by the FDA.
Most experts will use
the word "substitution,"
and in the resistance context,
we will refer to them as
resistance-associated
substitutions.
Some older literature will
also refer to them as
resistant-associated variants,
but that term is now
not the preferred term.
1:35
On this slide, there
is an illustration
of the relationships between
the different genotypes
and subtypes within
the genotypes,
showing how much variation
there is in genetic sequence.
This analysis is done as
a phylogenetic analysis
to illustrate the variation
between the viruses,
so it's an important takeaway
message from this slide,
that there is huge variation
in the hepatitis C virus.